JP Morgan Maintains Underweight on Novavax, Raises Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Eric Joseph maintains an Underweight rating on Novavax (NASDAQ:NVAX) but raises the price target from $8 to $9.
August 12, 2024 | 2:23 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan analyst Eric Joseph maintains an Underweight rating on Novavax but raises the price target from $8 to $9.
The Underweight rating suggests a bearish outlook, but the raised price target indicates some positive sentiment. The net impact is likely neutral in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100